Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes

被引：0
|
作者：
Kristoffer Sand
Jakob Theorell
Øystein Bruserud
Yenan T. Bryceson
Astrid Olsnes Kittang
机构：
[1] University of Bergen,Department of Clinical Science
[2] Karolinska University Hospital Huddinge,Center for Infectious Medicine, Department of Medicine, Karolinska Institutet
[3] Haukeland University Hospital,Division for Hematology, Department of Medicine
来源：
Cancer Immunology, Immunotherapy | 2016年 / 65卷
关键词：
Myelodysplastic syndromes; Cytotoxic T lymphocytes; CD57; CX3CR1; Granzyme B; Adhesion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1135 / 1147
页数：12
相关论文
共 50 条
  • [1] Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes
    Sand, Kristoffer
    Theorell, Jakob
    Bruserud, Oystein
    Bryceson, Yenan T.
    Kittang, Astrid Olsnes
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (09) : 1135 - 1147
  • [2] Treatment of patients with high-risk myelodysplastic syndromes
    Gattermann, Norbert
    Kuendgen, Andrea
    Germing, Ulrich
    [J]. CANCER TREATMENT REVIEWS, 2007, 33 : S64 - S68
  • [3] Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes
    Saft, Leonie
    Bjorklund, Elisabet
    Berg, Elisabeth
    Hellstrom-Lindberg, Eva
    Porwit, Anna
    [J]. LEUKEMIA RESEARCH, 2013, 37 (03) : 266 - 273
  • [4] Treatment of high-risk myelodysplastic syndromes
    Fenaux, Pierre
    [J]. HEMATOLOGIE, 2006, 12 : 12 - 13
  • [5] Treating high-risk myelodysplastic syndromes
    Ades, Lionel
    [J]. BULLETIN DU CANCER, 2023, 110 (11) : 1162 - 1167
  • [6] Management of high-risk myelodysplastic syndromes
    Pisani, FD
    Rainaldi, A
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 40 (03) : 215 - 228
  • [7] DECITABINE IN TREATMENT OF PATIENTS WITH INTERMEDIATEOR HIGH-RISK MYELODYSPLASTIC SYNDROMES
    Kalinichenko, E.
    Ponteleeva, I.
    Fiodarava, A.
    Iskrov, I.
    Uss, A.
    [J]. LEUKEMIA RESEARCH, 2017, 55 : S71 - S72
  • [8] High-risk myelodysplastic syndromes in hypomethylants failure
    Gardin, Claude
    [J]. HEMATOLOGIE, 2010, 16 : 24 - 28
  • [9] Histopathology in the diagnosis of high-risk myelodysplastic syndromes
    Kayano, Hidekazu
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2018, 58 (02) : 51 - 60
  • [10] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    Fenaux, P.
    Mufti, G. J.
    Hellstrom-Lindberg, E.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 395 - 395
12345